Metformin costs about five cents a pill. More than 150 million people worldwide swallow it every day to manage type 2 diabetes. Now a randomized, placebo-controlled trial published in 2026 has shown that the same drug can measurably slow the molecular machinery of aging in people who do not have diabetes at all.
The trial, called METFORAGING, enrolled older, non-diabetic adults living with HIV in Madrid and administered 850 mg of metformin twice daily over 24 weeks. Researchers tracked several leading epigenetic clocks, and participants who received metformin showed deceleration on the clocks most tightly linked to age-related disease and mortality, including GrimAge v2 and principal-component-derived measures. The findings land at a moment when the longevity field is watching closely for results from a much larger trial designed to test whether this generic medication can delay the diseases of aging across thousands of otherwise healthy older adults.
What the METFORAGING trial actually measured
Epigenetic clocks estimate biological age by reading chemical tags, called DNA methylation marks, that accumulate on the genome over a lifetime. Researchers have built several of these clocks, each calibrated to predict different outcomes. Horvath’s clock tracks chronological age. PhenoAge and GrimAge were trained on disease risk and mortality. The METFORAGING team ran participants’ blood samples through all of them, plus newer principal-component versions that reduce statistical noise.
In the metformin group, the clocks that best predict morbidity and death showed a consistent pattern: biological aging slowed relative to placebo. The trial’s double-blind, randomized design gives these findings considerably more weight than the observational studies that first hinted metformin users seemed to age more slowly. Still, the study was modest in size and enrolled a specific population, older adults with well-controlled HIV, which limits how broadly the conclusions can be applied to the general public.
Reinforcing signals from other trials
METFORAGING did not emerge in isolation. In a separate 24-week peer-reviewed study of virally suppressed older adults with HIV, researchers found that metformin reduced two inflammation-linked epigenetic clocks, PCPhenoAge and PCGrimAge, specifically inside monocytes. Monocytes are white blood cells that act as frontline drivers of chronic, low-grade inflammation, the kind of smoldering immune activation that accelerates heart disease, neurodegeneration, and frailty. Seeing metformin slow an aging clock inside these particular cells suggests the drug is acting on one of the core biological engines of age-related decline, not just shifting a generic metabolic dial.
Earlier human data pointed in the same direction. The MILES trial (registered as NCT02432287), a randomized, double-blind, placebo-controlled crossover study, gave healthy older adults 1,700 mg of metformin daily and then biopsied their skeletal muscle and fat tissue. The drug altered gene-expression pathways in both tissues, and the raw transcriptomic data were deposited in a public gene-expression database for independent verification. The affected pathways overlap with processes known to deteriorate with age: mitochondrial function, oxidative stress defense, and fatty acid metabolism. In short, metformin appeared to nudge older tissues toward a more youthful molecular profile.
The big trial the field is waiting for
The largest planned test of metformin as an aging therapy is TAME, Targeting Aging with Metformin. Designed to enroll roughly 3,000 adults aged 65 to 79 who do not have diabetes, TAME uses a composite endpoint that spans cardiovascular disease, cancer, cognitive decline, and death. The logic is deliberate: if one cheap pill can delay a cluster of age-related conditions simultaneously, it would constitute evidence that the drug acts on aging itself rather than on any single downstream illness.
The TAME framework was built with the U.S. Food and Drug Administration in mind. A positive result could establish “aging” as a treatable indication for the first time in regulatory history, opening the door for other interventions to be tested against the same target. But TAME has faced years of fundraising and logistical delays, and as of mid-2026, the field is still waiting for the trial to deliver the large-scale, multi-year outcome data that would move metformin from promising biomarker modifier to proven aging therapy.
The muscle problem
Not every signal points in a favorable direction. The MASTERS trial, a multicenter, randomized, double-blind, placebo-controlled study, found that metformin blunted the muscle-building benefits of progressive resistance exercise in older adults. The effect was modest in absolute terms, but the implication is serious: muscle mass and strength are among the strongest independent predictors of healthy aging, influencing mobility, fall risk, metabolic health, and the ability to live independently.
A drug that slows one set of aging markers while undermining muscle adaptation presents a genuine tension that researchers have not yet resolved. It remains unclear whether adjusting the dose, timing metformin away from workouts, or reserving the drug for people who cannot exercise vigorously would eliminate the tradeoff. The ANTHEM trial (registered as NCT04264897), a 12-week randomized controlled study with detailed metabolic phenotyping, is designed partly to address this gap. By stratifying participants according to baseline insulin sensitivity, ANTHEM could reveal whether metformin’s aging-related benefits depend on a person’s metabolic starting point and whether there is a profile of patient most likely to benefit without sacrificing physical performance.
Where the evidence stands as of mid-2026
The primary evidence now consists of registered, randomized, controlled trials with defined endpoints and, in several cases, publicly deposited datasets that other scientists can audit. METFORAGING, MILES, MASTERS, and the monocyte clock study all meet that standard. But they differ in population (people with HIV versus generally healthy older adults), duration (weeks to months, not years), and outcomes (molecular markers and muscle size, not heart attacks or dementia diagnoses). Those differences make it impossible to draw a single, simple conclusion about metformin and aging.
The most honest reading of the data is this: metformin clearly influences pathways tied to aging biology. It shifts epigenetic patterns, quiets inflammatory cell behavior, alters mitochondrial gene expression, and interferes with muscle adaptation to exercise. In some contexts, those changes look directionally favorable on the best available aging biomarkers. In others, the drug appears to work against a pillar of healthy aging that no pill can replace: physical strength.
Whether the net effect is beneficial will likely depend on who takes the drug, why they take it, and what they combine it with, especially exercise and nutrition. People considering metformin purely for longevity, outside a diabetes diagnosis or a clinical trial, are stepping ahead of what the science supports. The ongoing trials exist precisely to answer the questions that off-label self-experimentation cannot: Does metformin actually delay multiple age-related diseases in diverse, non-diabetic populations? Can its molecular benefits be captured without compromising strength and physical function? And can regulators be persuaded to recognize aging itself as a legitimate therapeutic target?
For now, metformin’s most secure role remains in the management of type 2 diabetes. Its potential as an aging intervention is being tested rigorously, clock by clock and trial by trial, and the next few years of data will determine whether a five-cent pill earns a place in a category of medicine that does not yet officially exist.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
